Stig Lennart Hansson

Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden.

Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna.

Arexis AB develops and manufactures pharmaceutical products. Its products are used for molecular dissection of metabolic and inflammatory diseases. The company was founded in 1999 and is headquartered in Goteborg, Sweden.

Uminova Invest AB is a regional venture capital firm formally established in 1992 and based in Umeå on the northern coast of Sweden. Since 2004 the shareholders of Uminova Invest include Uminova Holding AB, the holding company of Umeå University, as well as Industrifonden, Norrlandsfonden, Innovationsbron and Balticgruppen. The firm is part of the government-supported technology transfer and valorization system for academic research in Sweden, and has a strong regional focus.

Nanoxis AB provides tools and services for membrane protein research. It specializes in research and development of nanofabrication technologies in soft polymer and fluid-state liquid crystalline material. The company was founded by Owe Orwar and Anders Karlsson in November 2002 and is headquartered in Gothenburg, Sweden.

OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.

Lund University Bioscience AB (LU Bio) is an investment firm located in Lund, Sweden. In May 2007, LU Bio was founded by the parent firm, Lund University Development AB. They specialize in early-stage investments within the life sciences segment. Lund University was founded by the Swedish government in 1666. The university has three main research areas: medicine and pharmaceuticals, globally sustainable societal development, and the life sciences.

Avaris was founded in 2001 by research teams at the Karolinska Institute and Karolinska Innovations AB. The company is based on four proprietary technology platforms within cell and gene therapy. Avaris drives the research development and commercialization of new therapies in close collaboration with the founders, research teams, and strategic partners. The company is well positioned in cell and gene therapy field for chronic infections, cancer and inherited diseases. Avaris vision is to become the number one supplier of individualized cell and gene therapy treatments in northern Europe. In order to reach this goal it is exploring possibilities to acquire, or in license cell therapy technologies that complement the in house growth. Avaris is also open to partnering possibilities.

PharmaSurgics is a clinical stage biotech company developing novel treatments for the prevention of harmful scarring (adhesions) after surgery. Post-surgical adhesions develop in millions of patients every year and are a source of great patient suffering and enormous healthcare expenditures. The company was founded in 2005 after extensive research done by Dr Inger Mattsby-Baltzer, PhD and Professor Kjell Olmarker MD, PhD at the Sahlgrenska Academy. PharmaSurgics is based in Göteborg, Sweden, where comprehensive in vitro and in vivo facilities have been established.

Medtentia International Ltd. Oy is a holding company that develops solutions for mitral valve repair based on its proprietary helix ring concept. It is a medical technology company that creates solutions for cardiac interventions. It provides proprietary, helix-shaped products to address the unmet need in cardiac surgery. The company was founded by Dan Mogren and Olli U. Keränen in 2002 by Olli Keränen and is headquartered in Espoo, Finland.

Part of InDex Pharmaceuticals Holding AB, InDex Diagnostics AB manufactures pharmaceutical products. The company is based in Solna, Sweden. Peter Hakim Zerhouni has been the CEO of the Swedish company since 2015.

Beacon Software, Inc. is a software development management company based in New York, NY. Beacon Software, Inc. offers AI-powered assurance to help prevent software project failures. The company's platform provides instant project visibility, precise delivery and tracking, and real-time insights delivered before bottlenecks start. The CEO of the company is Jim Anderson.

Sixera Pharma AB conducts activities within research, development, and commercialization of pharmaceuticals. It develops treatment for Netherton syndrome. The company was founded by Jean Nordstrom on August 21, 2012 and is headquartered in Göteborg, Sweden.

InDex Pharmaceuticals AB is a pharmaceutical development company, which engages in the research, development of technology, and commercialization of scientific discoveries focusing on immunological diseases. It also offers the drug candidate cobitolimod and DiBiCol diagnostic kit. The company was founded was founded on December 14, 2015 and is headquartered in Solna, Sweden.

Cinclus Pharma AG is a Swiss Swedish pharmaceutical company founded in 2011. Cinclus Pharma is based in Basel, Switzerland. The private company is focused on bringing relief to people suffering from gastric acid related diseases, particularly gastroesophageal reflux disease (GERD). Cinclus Pharma's clinical stage drug candidate, linaprazan glurate, is a new approach to managing GERD and is showing promising results in acid control and lowering the cmax-value. The company was founded by experts in the field of GERD treatment with extensive experience from Astra and Astra Zeneca.

Malmö Industrifinans AB is a Swedish company that engages in buying and selling of shares.

Novel medical devices for minimal invasive cardiac valve surgery. Medtentia has completed preclinical validation for its first product. Investors Inveni Capital and Industrifonden will take the company through its clinical development phase. Early human trials have been completed successfully Q1 in 2009. Medtentia's technology is patented in USA and patent pending in Europe. Medtentia is a venture-backed medical device company focused on the development of minimally invasive and percutaneous heart valve repair and replacement devices on currently proven therapy. Medtentia will act on a global basis with its core activities and team located to Europe with main office in Helsinki Finland and in the Medicon Valley region of southern Sweden in Lund. Medtentia is currently developing a technology platform of products to enable rapid surgical mitral valve annulus repair and replacement, perform percutaneous mitral repair and replacement, leverage currently accepted therapeutic practice and reduce invasiveness, procedural time and morbidity.